Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

AHK-Cu

AHK-Cu is described as the copper(II) complex of the tripeptide L-alanyl-L-histidyl-L-lysine, a different material from GHK-Cu. No human administration study was found in the sources reviewed; the only evidence identified is one ex vivo hair-follicle and cell-culture study.

Aliases reviewed
L-alanyl-L-histidyl-L-lysine-Cu2+
Sources checked
2026-10-28
Editorial status
published

Evidence at a glance

Human
None foundNo human administration study was found; only ex vivo follicle and cell-culture work was identified.
Animal/cell
LimitedOne abstract-level study of human follicles ex vivo and cultured dermal papilla cells.
Approved medicine
None foundTwo Canadian drug-database name searches found no records; no approved use was verified.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.

Identity

AHK-Cu is described in the reviewed study as L-alanyl-L-histidyl-L-lysine-Cu2+, the copper(II) complex of the tripeptide alanine-histidine-lysine. Its first residue is alanine, so it is not GHK-Cu. PubChem lists the copper-free tripeptide L-alanyl-L-histidyl-L-lysine as a separate record from one that carries the synonym AHK-Cu and files the complex as a copper monohydrochloride. The salt form, copper ratio and purity of any catalogue material therefore cannot be assumed from the name.

Biological mechanism or research interest

The only AHK-Cu study identified in the sources reviewed is one laboratory study whose authors proposed that AHK-Cu supports hair-follicle growth by stimulating dermal papilla cell proliferation and limiting the apoptosis of those cells. The authors studied dermal papilla cells because they describe them as specialised fibroblasts that are important in the formation and growth of hair follicles. The proposed mechanism was examined only in laboratory models.

Verified approved human uses

Health Canada's Drug Product Database returned no active-ingredient records for the name searches AHK-CU and AHK on 2026-10-27. These are name-based searches, so an empty result does not by itself rule out a product recorded under another name, and a Canadian database does not establish status in other jurisdictions, which were not reviewed here. No approved human use was verified in the sources reviewed.

Investigational human evidence

No human administration study of AHK-Cu was found in the sources reviewed. The only AHK-Cu work identified used human hair follicles maintained outside the body (ex vivo) and dermal papilla cells grown in culture. These are laboratory models that use human tissue. They are not a clinical trial, and they did not measure hair growth, safety or tolerability in living people.

Claims that AHK-Cu regrows hair, treats hair loss or rejuvenates skin are not demonstrated human outcomes in the sources reviewed. The reviewed study measured follicle elongation outside the body, dermal papilla cell proliferation and apoptosis-related markers in culture. Its authors proposed, rather than established, a growth-promoting mechanism, and the study did not test skin outcomes or any product applied to people.

Human versus animal or cell evidence

In the 2007 study, AHK-Cu stimulated elongation of human hair follicles ex vivo and proliferation of cultured dermal papilla cells under the tested laboratory conditions. Treated cells showed a higher Bcl-2/Bax ratio and lower levels of cleaved caspase-3 and PARP. The reduction in apoptotic cells measured by flow cytometry was not statistically significant. No animal study of AHK-Cu was identified in the sources reviewed, and the human-tissue findings come from laboratory culture, not from people.

Limitations and known risks

The evidence rests on a single laboratory study, reviewed at abstract level; no independent replication was found in the sources reviewed. The sources reviewed did not establish skin penetration, human safety, irritation or sensitisation, copper exposure or long-term effects. Effects seen in cultured follicles and cells do not show that the material would act the same way in people. The identity, salt form, purity and copper content of any catalogue material are unverified.

What this profile is—and is not

Concise source review from primary and regulatory records, independently checked for source accuracy; supplier listings were used only to find the name. Recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.